Tunable work function has a high profile for the MXene-based optoelectronic devices, and surface modification provides the huge potential to shift its Fermi level and modulate the work function. In this work, the window of MXene's work function is engineered from 4.55 to 5.25 eV by surface modification with LiF, Se, and polyethylenimine ethoxylated (PEIE). The vertical p-CsCu 2 I 3 /n-Ca 2 Nb 3-x Ta x O 10 junction photodetectors are constructed on the basis of the above surfacemodified MXenes, which changes the Schottky barrier between n-Ca 2 Nb 3-x Ta x O 10 and the electrodes. In particular, the rectification effect is significantly enhanced by utilizing PEIE-decorated MXene electrodes, resulting in a high rectification ratio of 16 136 and improved UV responsivity of 81.3 A W -1 . Such high-performance devices based on MXenes electrodes are compatible with the standard clean room fabrication process, realizing large-scale flexible UV detectors that maintain 80% of the original current after 5000 times bending. Meanwhile, a photodetector array stimulated with UV of different wavelengths is constructed to reveal its potential for image sensing. Finally, functional "AND" and "OR" optoelectronic logic gates are developed for UV communication using Au/ CsCu 2 I 3 /Ca 2 Nb 3-x Ta x O 10 /MXene-PEIE photodetectors, enriching the application of MXene-based optoelectronic devices. This work on tuning MXene work function via surface modification demonstrates that MXene is a promising candidate for future optoelectronics.
Chaperone-mediated autophagy (CMA) is a selective type of autophagy whereby a specific subset of intracellular proteins is targeted to the lysosome for degradation. The present study investigated the mechanisms underlying the response and resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines. In engineered 5-FU-resistant CRC cell lines, a significant elevation of lysosome-associated membrane protein 2A (LAMP2A), which is the key molecule in the CMA pathway, was identified. High expression of LAMP2A was found to be responsible for 5-FU resistance and to enhance PLD2 expression through the activation of NF-κB pathway. Accordingly, loss or gain of function of LAMP2A in 5-FU-resistant CRC cells rendered them sensitive or resistant to 5-FU, respectively. Taken together, the results of the present study suggested that chemoresistance in patients with CRC may be mediated by enhancing CMA. Thus, CMA is a promising predictor of chemosensitivity to 5-FU treatment and anti-CMA therapy may be a novel therapeutic option for patients with CRC.
Aneurysmal subarachnoid hemorrhage (aSAH) is an acute cerebrovascular disease that seriously damages the central nervous system and simultaneously exerts pathophysiological effects on multiple organs of the body, with high mortality and morbidity. 1,2 Approximately onethird of the survivors suffer from severe disability and functional dependency. 3 Rebleeding is a major early complication of aSAH with the incidence of 6%-23%, which most occurs within 72 hours of onset. 4,5 Previous studies reported that the mortality was 50%-60% in the presence of rebleeding. 4-6 To date, craniotomy clipping and endovascular embolization serve as main treatments for aSAH to prevent and treat complications such as rebleeding, vasospasm and hydrocephalus, and to reduce the occurrences of deaths and disabilities. 7-11 Although improvements in intensive care and treatments in recent years, the prognosis is still a frequent concern for aSAH. To the best of our knowledge,
Increased RV FDG uptake was associated with RV dysfunction and may be a prognostic predictor of all-cause mortality or heart transplantation in patients with DCM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.